Genscript Biotech Corporation Financial Flexibility Index
Genscript Biotech Corporation financial flexibility index. Genscript Biotech Corporation (G51) has a Financial Flexibility Index of -0.04x as of June 2023. Free cash flow of €-53.49 Million (operating CF €-93.58 Million minus capex €40.10 Million) represents 0% of total liabilities (€1.30 Billion). Explore Genscript Biotech Corporation (G51) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Genscript Biotech Corporation (2016–2025)
Financial flexibility index of Genscript Biotech Corporation from 2016 to 2025. Historical Financial Flexibility Index trend for Genscript Biotech Corporation across 10 annual periods. Check G51 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Genscript Biotech Corporation Financial Flexibility Index by Year (2016–2025)
Genscript Biotech Corporation financial flexibility index by year from 2016 to 2025. Year-by-year free cash flow to debt coverage for Genscript Biotech Corporation. For the full cash flow conversion analysis, see G51 cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.46x | €409.36 Million | €325.52 Million | €888.59 Million | ▲ +96.8% |
| 2024 | 0.23x | €223.57 Million | €75.65 Million | €954.91 Million | ▲ +343.4% |
| 2023 | -0.10x | €-129.20 Million | €-286.91 Million | €1.34 Billion | ▼ -236.7% |
| 2022 | 0.07x | €83.28 Million | €-120.29 Million | €1.18 Billion | ▲ +2240.7% |
| 2021 | 0.00x | €-3.75 Million | €-136.79 Million | €1.14 Billion | ▲ +92.9% |
| 2020 | -0.05x | €-29.21 Million | €-151.09 Million | €631.82 Million | ▼ -129.7% |
| 2019 | 0.16x | €80.42 Million | €-29.95 Million | €517.11 Million | ▼ -82.6% |
| 2018 | 0.89x | €378.50 Million | €307.66 Million | €423.68 Million | ▲ +387.4% |
| 2017 | 0.18x | €50.58 Million | €21.37 Million | €275.94 Million | ▼ -81.8% |
| 2016 | 1.01x | €42.26 Million | €33.27 Million | €42.01 Million | — |